Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.36 |
| ▸ | PRKCA | P17252 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
| ▸ | ACACA | Q13085 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23586586 | 0.95 | CYP4F2 (0.45) | CYP4F2CYP4A11TSHRPRKCAALDH1A1 | |
| SCHEMBL21757419 | 0.89 | TSHR (0.38) | CYP4F2CYP4A11TSHRPRKCAALDH1A1 | |
| SCHEMBL1908743 | 0.84 | CYP4F2 (0.43) | CYP4F2CYP4A11TSHRPRKCAALDH1A1 | |
| SCHEMBL1911530 | 0.84 | CYP4F2 (0.47) | CYP4F2CYP4A11TSHRPRKCAALDH1A1 | |
| SCHEMBL20875724 | 0.82 | CYP4F2 (0.42) | CYP4F2CYP4A11TSHRPRKCAALDH1A1 | |
| SCHEMBL1911430 | 0.82 | CYP4F2 (0.50) | CYP4F2CYP4A11TSHRPRKCAL3MBTL1 | |
| SCHEMBL21757361 | 0.81 | TSHR (0.33) | TSHRPRKCAALDH1A1TDP1L3MBTL1 | |
| SCHEMBL9483233 | 0.81 | CYP4F2 (0.47) | CYP4F2CYP4A11TSHRTDP1ACLY | |
| SCHEMBL20747669 | 0.81 | CYP4F2 (0.53) | CYP4F2CYP4A11TSHRALDH1A1L3MBTL1 | |
| SCHEMBL10087754 | 0.81 | CYP4F2 (0.53) | CYP4F2CYP4A11TSHRALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119552069-A | Improved preparation method of gemfibrozil | 山东精进药业有限公司 | 2025-03-04 | — | — | CN | claimed |
| CN-113105377-B | Preparation method of plasticizer and application of plasticizer in plastic product | 新疆欣业恒达塑业有限公司 | 2022-09-02 | — | — | CN | claimed |
| CN-113105377-A | Preparation method of plasticizer and application of plasticizer in plastic product | 程伟 | 2021-07-13 | — | — | CN | claimed |
| CN-112592275-A | Preparation method of isobutyl 5-chloro-2, 2-dimethylpentanoate | 杭州宇龙化工有限公司 | 2021-04-02 | — | — | CN | claimed |
| CN-1012896-B | 5-(2, the 5-dimethyl phenoxy)-2,2-dimethyl valeric acid preparation method's improvement | WARNER LAMBERT CO (US) | 1991-06-19 | — | — | CN | claimed |
| EP-0226161-B1 | IMPROVED PROCESS FOR PREPARING 5-(2,5-DIMETHYLPHENOXY)-2,2-DIMETHYLPENTANOIC ACID | WARNER-LAMBERT COMPANY (US) | 1989-11-08 | — | — | EP | claimed |
| CN-86108472-A | 5-(2, the 5-dimethyl phenoxy)-2,2-dimethyl valeric acid preparation method's improvement | — | 1987-07-22 | — | — | CN | claimed |
| EP-0226161-A1 | Improved process for preparing 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid | WARNER-LAMBERT COMPANY (US) | 1987-06-24 | — | — | EP | claimed |
| US-4665226-A | Process for preparing 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid | WARNER-LAMBERT COMPANY (US) | 1987-05-12 | — | — | US | claimed |
| EP-4686757-A1 | INHIBITORS OF EXPRESSION AND/OR FUNCTION | e-therapeutics PLC (GB) | 2026-02-04 | — | — | EP | disclosed |
| CN-121342645-A | Preparation method of gemfibrozil Ji Zazhi A key intermediate | 山东精进药业有限公司 | 2026-01-16 | — | — | CN | disclosed |
| CN-121248394-A | Synthesis method of gemfibrozil Ji Zazhi A | 山东精进药业有限公司 | 2026-01-02 | — | — | CN | disclosed |
| US-20250313522-A1 | PHENOXY CARBOXYLIC ACID COMPOUNDS AND MEDICAL USES THEREOF | QINGDAO RISING BIOTECHNOLOGY CO., LTD (CN) | 2025-10-09 | — | — | US | disclosed |
| US-12365643-B2 | Phenoxy carboxylic acid compounds and medical uses thereof | QINGDAO RISING BIOTECHNOLOGY CO., LTD (CN) | 2025-07-22 | — | — | US | disclosed |
| CN-101613334-A | Flavone derivative and medicinal use thereof | INST PHARM & TOXICOLOGY AMMS | 2009-12-30 | — | — | CN | disclosed |
| CN-1012896-B | 5-(2, the 5-dimethyl phenoxy)-2,2-dimethyl valeric acid preparation method's improvement | WARNER LAMBERT CO (US) | 1991-06-19 | — | — | CN | disclosed |
| EP-0226161-B1 | IMPROVED PROCESS FOR PREPARING 5-(2,5-DIMETHYLPHENOXY)-2,2-DIMETHYLPENTANOIC ACID | WARNER-LAMBERT COMPANY (US) | 1989-11-08 | — | — | EP | disclosed |
| CN-86108472-A | 5-(2, the 5-dimethyl phenoxy)-2,2-dimethyl valeric acid preparation method's improvement | — | 1987-07-22 | — | — | CN | disclosed |
| EP-0226161-A1 | Improved process for preparing 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid | WARNER-LAMBERT COMPANY (US) | 1987-06-24 | — | — | EP | disclosed |
| US-4665226-A | Process for preparing 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid | WARNER-LAMBERT COMPANY (US) | 1987-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365643-B2 | Phenoxy carboxylic acid compounds and medical uses thereof | PYGL, SLC10A1, GYS2 | CYP4F2 116/4885CYP4A11 6/4885TSHR 2525/4885 |
| US-20250313522-A1 | PHENOXY CARBOXYLIC ACID COMPOUNDS AND MEDICAL USES THEREOF | PYGL, SLC10A1, GYS2 | CYP4F2 116/4885CYP4A11 6/4885TSHR 2525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.